So PEB was gilding the lily when it stated in May 2013 that Obamacare would be great for its business in the US?
Printable View
Economics 101 would be to sell fewer units at a higher price if it maximises your profit over selling more units at a lower price, Skid. PEB isn't in a perfectly competitive market - it has a relatively unique product with high barriers to entry, and is a disruptor in it's field.
I left the medical insurance industry prior to PEB being released in the market, but have specifically worked in cost containment areas in both the US and Singapore
http://www.reuters.com/article/us-us...-idUSKBN1360DC
It is way too early to assume anything re PEB's chances in the USA arising from the likely dismantling of Obama care. Indeed there are already reports emerging (RNZ News) that Obama care won't be axed in entirety.
I doubt PEB were 'guilding the lily' way back in 2013. Merely stating a facts as they saw them way back then, and thank you Grunter for your views.
Times are changing, and good companies will be measured by how they cope with these changes.
Ongoing insurance issue's,
Charging $3000 for a test you can purchase for $350Au is BS.
https://www.google.com.au/url?sa=t&s...WsnenSE8sQHIRQ
https://www.google.com.au/url?sa=t&s...OOXfyyFmiKV7kA
Looks good..... still early days and still awaiting financial update 24 Nov.
POSITIVE RESULTS IN KAISER PERMANENTE USER PROGRAMME
Cancer diagnostics company Pacific Edge (NZX: PEB) has advised that it has
successfully completed its analysis of the data from the large scale Kaiser
Permanente (Kaiser) User Programme with positive and compelling findings.
The performance of Pacific Edge's Cxbladder Triage test was evaluated in a
large, blinded study (User Programme) on consenting Kaiser patients, with
findings equivalent to the previously published performance for Cxbladder
Triage. Kaiser is currently completing its own analysis of the data, with the
joint analysis to be submitted for scientific and clinical publication.
The next test is whether or not PEB can secure an exclusive contract, good test results are good, but if it just means they are given access to compete with several other competitive providers, some of whom will be entrenched, some of whom are new and innovative like Cxbladder, than this user programme is worth really very little.
Hopefully they can show some hard ball commercial negotiation skills and make something of it, what are the odds ?